Patent granted in USA 2017 and licensed to Myogem “CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2”.

Note on “Justia Patents”: https://patents.justia.com/patent/20170304309

PATENT:

Artero Allepuz, R., Castells Boliart, J., Borrell Bilbao, J. I., Llamusí Troísi, B., Bargiela Schönbrunn, A., Konieczny, P., Pascual-Gilabert, M., Teixidó Closa, J., Estrada Tejedor, R., & López González, A. (2017). Caffeine for the treatment of myotonic dystrophy type 1 and type 2 (U.S. Patent Application No. US 2017/0304309 A1). United States Patent and Trademark Office. Published on October 26, 2017.

View report

MyoDM, a breakthrough in the treatment of Steinert's Myotonic Dystrophy. Research and innovation at the service of your well-being.
Buy now

¿Do you have any questions
or need more information?

Fill out the form and our team will respond as soon as possible.
Email *
Subject *
Message *

Related news.

Scientific article with a complete overview through 2022 of the most recent drug development programs undergoing preclinical and clinical evaluation.

View report
Ver más

Doctoral thesis

Highest qualification awarded by the Thesis Committee: Dr. Rafael Mañez Mendiluce**, Dr. Carmen Escolano Mirón***, Arturo López Castel****
Ver más

Scientific article compiling the most recent drug development projects currently in the preclinical and clinical phases

View report
Ver más